[go: up one dir, main page]

US20070190105A1 - Local system for the release of active principle and process for its manufacture - Google Patents

Local system for the release of active principle and process for its manufacture Download PDF

Info

Publication number
US20070190105A1
US20070190105A1 US11/620,172 US62017207A US2007190105A1 US 20070190105 A1 US20070190105 A1 US 20070190105A1 US 62017207 A US62017207 A US 62017207A US 2007190105 A1 US2007190105 A1 US 2007190105A1
Authority
US
United States
Prior art keywords
polymerisation
polymethyl methacrylate
paste
release
local system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/620,172
Inventor
Klaus-Dieter Kuhn
Sebastian Vogt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kulzer GmbH
Original Assignee
Heraeus Kulzer GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heraeus Kulzer GmbH filed Critical Heraeus Kulzer GmbH
Assigned to HERAEUS KULZER GMBH reassignment HERAEUS KULZER GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: VOGT, SEBASTIAN, KUHN, KLAUS-DIETER
Publication of US20070190105A1 publication Critical patent/US20070190105A1/en
Priority to US12/949,260 priority Critical patent/US8758827B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/16—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J2200/00—General characteristics or adaptations
    • A61J2200/20—Extrusion means, e.g. for producing pharmaceutical forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A61L2300/406—Antibiotics

Definitions

  • the object of the invention is a locally effective system for the release of active principle which system consists of approximately spherical or rotation symmetrical bodies which are composed essentially of polymethyl methacrylate or polymethyl methacrylate co-methyl acrylate, zirconium dioxide or barium sulphate and one or more pharmaceutical active principles.
  • Osteomyelitis can be hematogenous, post-traumatic or postoperative. Particularly difficult to treat is the chronic form of osteomyelitis which, in extreme cases, can lead to the loss of limbs and even to septicaemia.
  • a common method is surgical remediation by radical surgical debridement. During this procedure, the infected or necrotic bone is excised extensively. Subsequently, the bone cavity is filled with a local carrier of antibiotics or treated by repeated rinse-suction drainage. As a result of the local release of large quantities of antibiotics, the bacterial germs remaining in the adjacent bone areas, too, are effectively controlled when using a sufficiently bone-accessible bactericidal antibiotic such as gentamicin sulphate and clindamycin hydrochloride.
  • a sufficiently bone-accessible bactericidal antibiotic such as gentamicin sulphate and clindamycin hydrochloride.
  • this active principle carrier it was proposed by Heuser and Dingeldein in 1978, to add glycine or other amino acids to improve the release of the antibiotic (DE 26 51 441). Following contact with the discharge from the wound, the incorporated amino acids are dissolved and form pore systems from which the active principle is able to diffuse out. In this way an improved release of active principle is achieved.
  • Gentamicin is an antibiotic which is extremely thermally stable. In view of the increasing spread of resistant and, in particular, multi-resistant bacteria, however, further antibiotics are desirable in local systems for the release of active principle. Unfortunately, these antibiotics, such as vancomycin and teicoplanin are thermally unstable. As a result, it has not been possible so far to produce local systems for the release of active principle with these antibiotics by injection moulding.
  • EP 796 712 An alternative in this respect is suggested in EP 796 712, according to which it is possible to produce implant materials using thermally labile active principles.
  • a conventional PMMA bone cement is mixed with one or several antibiotics and transferred into corresponding moulds made of plastic, for example.
  • Conventional PMMA bone cements consist of a powder component—composed of a polymer powder, an opaquer for x-ray beams and a polymerisations initiator—and a liquid monomer component containing methyl methacrylate, a stabilisator and a polymerisation activator. After mixing both components, the polymerisation activator and the polymerisation initiator meet each other and radical polymerisation of the methyl methacrylate is initiated.
  • the invention is based on the object of developing a locally effective system for the release of active principle which can be produced continuously.
  • the production process is to make it possible to integrate also thermally labile antibiotics into the systems for the release of active principle.
  • the disadvantages of the processes described in DE 23 20 373 and EP 796 712 are to be overcome.
  • the object has been achieved by developing a local system for the release of active principle which system consists of spherical bodies which are composed essentially of polymethyl methacrylate or polymethyl methacrylate co-methyl acrylate, zirconium dioxide or barium sulphate and a pharmaceutical active principle and which are produced by radical polymerisation, radical polymerisation activators effective in the temperature range of 10-80° C. or residues of such polymerisation activators, in particular from the groups of aromatic amines, heavy metal salts and barbiturates not being contained therein.
  • system for the release of active principle according to the invention does not contain N,N-dimethyl aniline, N,N-dimethyl-p-toluidine, N,N,-bis-hydroxyethyl-p-toluidine or their consequential products formed during the initiation of radical polymerisation.
  • the invention also relates to a process for the production of the local active principle system in the case of which
  • Heating can be effected e.g. by the effect of infrared radiation or by the effect of hot air or by the effect of microwaves.
  • Thermally decomposing radical initiators which the expert would consider as commonly used are in particular those from the group consisting of dibenzoyl peroxide, dilauroyl peroxide and azoisobutyrodinitrile.
  • a wire is preferably used which is preheated to a temperature in the region of the de-composition temperature of the thermal initiator.
  • the injection moulding tool is preferably made of Teflon or another inert plastic.
  • approximately spherical bodies with a diameter of 7 mm are injection moulded by means of an injection moulding device on a polyfilic, surgical steel wire. The spray moulding process takes place at room temperature. Subsequently, the bodies are hardened in a dryer tunnel at a temperature of 80° C.
  • the bodies formed have a mass of ⁇ 240 mg.
  • a paste of 570.0 g of polymethyl methacrylate co-methyl acrylate (molecular weight 800,000 g/mole), 285.0 g of methyl methacrylate, 89.0 g of zirconium dioxide, 45.0 g of vancomycin hydrochloride, 8.8 g of a mixture of dibenzoyl peroxide and water in a weight ratio of 3:1 and 15.0 g of glycine is produced by intense mixing.
  • approximately spherical bodies with a diameter of 7 mm are injection moulded by means of an injection moulding device on a polyfilic, surgical steel wire. Immediately afterwards, the bodies are hardened continually with a heating radiator while the injection-moulded bodies are heated to 60-70° C. by the effect of IR radiation and polymerisation is initiated.
  • the cured bodies have a mass of ⁇ 240 mg.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)

Abstract

A local system for the release of active principle is described which consists of approximately spherical or rotation symmetrical bodies which are composed essentially of polymethyl methacrylate or polymethyl methacrylate co-methyl acrylate, zirconium dioxide or barium sulphate and one or more pharmaceutical active principles, in particular antibiotics, and which are produced by radical polymerisation, radical polymerisation activators effective in the temperature range of 10-80° C. or residues of these polymerisation activators from the groups of aromatic amines, heavy metal salts and barbiturates not being contained therein.
A process for the production of the local system for the release of active principle in the case of which
    • a) a paste is produced by mixing methyl methacrylate, polymethyl methacrylate or poly-methyl methacrylate co-methyl acrylate, zirconium dioxide and/or barium sulphate, one or more pharmaceutical active principles and a thermally decomposing radical initiator, the paste having a viscosity such that it cannot be deformed at room temperature by the effect of gravity;
    • b) the paste is injection moulded by an injection moulding device without heating at room temperature into approximately spherical or rotation-symmetrical bodies or the approximately spherical or rotation symmetrical bodies are injection-moulded onto a wire;
    • c) the bodies are heated to a temperature at which the polymerisation initiator decomposes.

Description

  • The object of the invention is a locally effective system for the release of active principle which system consists of approximately spherical or rotation symmetrical bodies which are composed essentially of polymethyl methacrylate or polymethyl methacrylate co-methyl acrylate, zirconium dioxide or barium sulphate and one or more pharmaceutical active principles.
  • One of the major challenges in bone surgery is even today posed by the treatment of osteomyelitis. Osteomyelitis can be hematogenous, post-traumatic or postoperative. Particularly difficult to treat is the chronic form of osteomyelitis which, in extreme cases, can lead to the loss of limbs and even to septicaemia.
  • A common method is surgical remediation by radical surgical debridement. During this procedure, the infected or necrotic bone is excised extensively. Subsequently, the bone cavity is filled with a local carrier of antibiotics or treated by repeated rinse-suction drainage. As a result of the local release of large quantities of antibiotics, the bacterial germs remaining in the adjacent bone areas, too, are effectively controlled when using a sufficiently bone-accessible bactericidal antibiotic such as gentamicin sulphate and clindamycin hydrochloride.
  • Spherical local systems for the release of active principle composed of polymethyl methacrylate, zirconium dioxide and an antibiotic were described for the first time by Klaus Klemm in 1975 (DE 23 20 373). This concept proved to be basically successful although it had the disadvantage that only a small part of the active principle contained in the spheres was released.
  • As a further development of this active principle carrier, it was proposed by Heuser and Dingeldein in 1978, to add glycine or other amino acids to improve the release of the antibiotic (DE 26 51 441). Following contact with the discharge from the wound, the incorporated amino acids are dissolved and form pore systems from which the active principle is able to diffuse out. In this way an improved release of active principle is achieved.
  • Local systems for the release of active principle composed mainly of polymethyl methacrylate, an opaquer for x-ray beams and an antibiotic can be produced either by a special injection moulding process (DE 23 20 373) or by casting antibiotic-containing polymethyl methacrylate bone cements in special moulds (EP 796 712). Injection moulding has the crucial disadvantage that temperatures of >120° C. are required in order to melt the polymer. As a result, it is not possible to integrate thermally labile antibiotics or other thermally labile active principles into these local systems for the release of active principles. As a result, the system for the release of active principle charged with gentamicin, which is produced by conventional injection moulding, has been the only one to be available on the market under the name of Septopal®. Gentamicin is an antibiotic which is extremely thermally stable. In view of the increasing spread of resistant and, in particular, multi-resistant bacteria, however, further antibiotics are desirable in local systems for the release of active principle. Unfortunately, these antibiotics, such as vancomycin and teicoplanin are thermally unstable. As a result, it has not been possible so far to produce local systems for the release of active principle with these antibiotics by injection moulding.
  • An alternative in this respect is suggested in EP 796 712, according to which it is possible to produce implant materials using thermally labile active principles. During this process, a conventional PMMA bone cement is mixed with one or several antibiotics and transferred into corresponding moulds made of plastic, for example. Conventional PMMA bone cements consist of a powder component—composed of a polymer powder, an opaquer for x-ray beams and a polymerisations initiator—and a liquid monomer component containing methyl methacrylate, a stabilisator and a polymerisation activator. After mixing both components, the polymerisation activator and the polymerisation initiator meet each other and radical polymerisation of the methyl methacrylate is initiated. After a few minutes, the PMMA bone cement has been cured. As a result of this curing behaviour, it is possible to produce chain-type systems for the release of active principle by means of the moulds proposed in EP 796 712 by using conventional PMMA bone cements only in a batchwise process. Continuous production under industrial conditions is consequently not possible. In the case of this manufacturing process, N,N-dimethyl-p-toluidine is used as polymerisation activator in the PMMA bone cement.
  • The invention is based on the object of developing a locally effective system for the release of active principle which can be produced continuously. The production process is to make it possible to integrate also thermally labile antibiotics into the systems for the release of active principle. The disadvantages of the processes described in DE 23 20 373 and EP 796 712 are to be overcome.
  • The object has been achieved by developing a local system for the release of active principle which system consists of spherical bodies which are composed essentially of polymethyl methacrylate or polymethyl methacrylate co-methyl acrylate, zirconium dioxide or barium sulphate and a pharmaceutical active principle and which are produced by radical polymerisation, radical polymerisation activators effective in the temperature range of 10-80° C. or residues of such polymerisation activators, in particular from the groups of aromatic amines, heavy metal salts and barbiturates not being contained therein.
  • In particular, the system for the release of active principle according to the invention does not contain N,N-dimethyl aniline, N,N-dimethyl-p-toluidine, N,N,-bis-hydroxyethyl-p-toluidine or their consequential products formed during the initiation of radical polymerisation.
  • The invention also relates to a process for the production of the local active principle system in the case of which
      • a) a paste is produced by mixing methyl methacrylate, polymethyl methacrylate or poly-methyl methacrylate co-methyl acrylate, zirconium dioxide and/or barium sulphate, one or more pharmaceutical active principles and a thermally decomposing radical initiator, the paste having a viscosity such that it is not deformed at room temperature by the effect of gravity;
      • b) the paste is injection moulded by an injection moulding device without heating at room temperature into approximately spherical or rotation symmetrical bodies or the approximately spherical or rotation symmetrical bodies are injection-moulded onto a wire;
      • c) the bodies are heated to a temperature at which the polymerisation initiator decomposes.
  • Heating can be effected e.g. by the effect of infrared radiation or by the effect of hot air or by the effect of microwaves.
  • It is important for the bodies produced from the paste to be mechanically stable before curing to such an extent that these are not deformed as a result of their inherent mass by the effect of gravity or, if the bodies are injection-moulded onto threads, become detached from the threads.
  • Thermally decomposing radical initiators which the expert would consider as commonly used are in particular those from the group consisting of dibenzoyl peroxide, dilauroyl peroxide and azoisobutyrodinitrile.
  • In step b) a wire is preferably used which is preheated to a temperature in the region of the de-composition temperature of the thermal initiator. By preheating the wire it is possible to initiate polymerisation in the interior of the injection moulded body before curing is effected by the effect of infrared radiation, hot air or by microwaves. As a result, the bodies adhere in a particularly stable manner on the wire.
  • The injection moulding tool is preferably made of Teflon or another inert plastic.
  • The invention will be explained by the following examples though without restricting the invention.
    • EXAMPLE 1
  • A paste of 570.0 g of polymethyl methacrylate co-methyl acrylate (molecular weight 800,000 g/mole), 285.0 g of methyl methacrylate, 89.0 g of zirconium dioxide, 42.0 g of gentamicin sulphate (AK 600), 8.8 g of a mixture of dibenzoyl peroxide and water in a weight ratio of 3:1 and 15.0 g of glycine is produced by intense mixing. Using this viscous paste, approximately spherical bodies with a diameter of 7 mm are injection moulded by means of an injection moulding device on a polyfilic, surgical steel wire. The spray moulding process takes place at room temperature. Subsequently, the bodies are hardened in a dryer tunnel at a temperature of 80° C. The bodies formed have a mass of ˜240 mg.
    • EXAMPLE 2
  • A paste of 570.0 g of polymethyl methacrylate co-methyl acrylate (molecular weight 800,000 g/mole), 285.0 g of methyl methacrylate, 89.0 g of zirconium dioxide, 45.0 g of vancomycin hydrochloride, 8.8 g of a mixture of dibenzoyl peroxide and water in a weight ratio of 3:1 and 15.0 g of glycine is produced by intense mixing. Using the paste formed, approximately spherical bodies with a diameter of 7 mm are injection moulded by means of an injection moulding device on a polyfilic, surgical steel wire. Immediately afterwards, the bodies are hardened continually with a heating radiator while the injection-moulded bodies are heated to 60-70° C. by the effect of IR radiation and polymerisation is initiated. The cured bodies have a mass of ˜240 mg.

Claims (8)

1. A local system for the release of active principle which consists of approximately spherical or rotation symmetrical bodies which are composed essentially of polymethyl methacrylate or polymethyl methacrylate co-methyl acrylate, zirconium dioxide or barium sulphate and one or more pharmaceutical active principles, and which are produced by radical polymerisation, wherein radical polymerisation activators effective in the temperature range of 10-80° C. or residues of these polymerisation activators selected from the group consisting of aromatic amines, heavy metal salts and barbiturates are not contained therein.
2. Local system for the release of active principle according to claim 1, wherein N,N-dimethyl aniline, N,N-dimethyl-p-toluidine, N,N,-bis-hydroxyethyl-p-toluidine or their consequential products formed during the initiation of radical polymerisation are not contained therein.
3. Process for the production of the local system of claim 1 which comprises
a) producing a paste by mixing methyl methacrylate, polymethyl methacrylate or polymethyl methacrylate co-methyl acrylate, zirconium dioxide and/or barium sulphate, one or more pharmaceutical active principles and a thermally decomposing radical initiator, the paste having a viscosity sufficient to prevent deformation at room temperature by the effect of gravity;
b) injection moulding the paste by an injection moulding device without heating at room temperature into approximately spherical or rotationally symmetrical bodies or injection moulding approximately spherical or rotation symmetrical bodies onto a wire;
c) heating the bodies to a temperature at which the polymerisation initiator decomposes.
4. Process according to claim 3, wherein in step c) heating is by the effect of infrared radiation or by the effect of air or by the effect of microwaves.
5. Process according to claim 3, wherein the decomposing radical initiator is one or more of the substances selected from the group consisting of dibenzoyl peroxide, dilauroyl peroxide and azoisobutyrodinitrile.
6. Process according to claim 3, wherein in step b) a wire is used which is preheated to a temperature in the region of the decomposition temperature of the thermal initiator.
7. Process according to claim 3, wherein the injection moulding tool is made of Teflon or another inert plastic.
8. The local system of claim 1, wherein said active principles are antibiotics.
US11/620,172 2006-02-10 2007-01-05 Local system for the release of active principle and process for its manufacture Abandoned US20070190105A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/949,260 US8758827B2 (en) 2006-02-10 2010-11-18 Local system for the release of active principle and process for its manufacture

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006006510.7 2006-02-10
DE102006006510A DE102006006510A1 (en) 2006-02-10 2006-02-10 Local drug delivery system and a method for its production

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/949,260 Division US8758827B2 (en) 2006-02-10 2010-11-18 Local system for the release of active principle and process for its manufacture

Publications (1)

Publication Number Publication Date
US20070190105A1 true US20070190105A1 (en) 2007-08-16

Family

ID=38080014

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/620,172 Abandoned US20070190105A1 (en) 2006-02-10 2007-01-05 Local system for the release of active principle and process for its manufacture
US12/949,260 Expired - Fee Related US8758827B2 (en) 2006-02-10 2010-11-18 Local system for the release of active principle and process for its manufacture

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/949,260 Expired - Fee Related US8758827B2 (en) 2006-02-10 2010-11-18 Local system for the release of active principle and process for its manufacture

Country Status (9)

Country Link
US (2) US20070190105A1 (en)
EP (1) EP1818039B1 (en)
JP (1) JP4686488B2 (en)
CN (1) CN101015697B (en)
AU (1) AU2007200072B2 (en)
BR (1) BRPI0700258A (en)
CA (1) CA2572764A1 (en)
DE (1) DE102006006510A1 (en)
ZA (1) ZA200701174B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110112210A1 (en) * 2008-06-30 2011-05-12 Heraeus Medical Gmbh Pmma paste

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007052116B4 (en) * 2007-10-22 2013-02-21 Heraeus Medical Gmbh One-component bone cement pastes, their use and methods of curing them
DE102007050762B3 (en) * 2007-10-22 2009-05-07 Heraeus Medical Gmbh Paste polymethyl methacrylate bone cement and its use
DE102008030312A1 (en) * 2008-06-30 2010-01-14 Heraeus Medical Gmbh Polymethylmethacrylate-based paste used in single- or two-component bone cements or active substance release systems, has self-sterile composition
CA2797904C (en) * 2011-12-20 2015-01-27 Heraeus Medical Gmbh Paste-like bone cement
EP2664349B1 (en) * 2012-05-16 2016-02-03 Heraeus Medical GmbH Bone cement in paste form

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3882858A (en) * 1973-04-21 1975-05-13 Merck Patent Gmbh Surgical synthetic-resin material and method of treating osteomyelitis
US4191740A (en) * 1976-11-11 1980-03-04 Merck Patent Gesellschaft Mit Beschrankter Haftung Synthetic resin-base, antibiotic compositions containing amino acids
US4782118A (en) * 1985-06-20 1988-11-01 Ceraver, S.A. Cement for fixing a bone prosthesis
US5958465A (en) * 1996-02-22 1999-09-28 Merck Patent Gesellschaft Apparatus for the production of drug-containing implants in the form of strings of beads
US6160033A (en) * 1996-08-22 2000-12-12 Merck Patent Gesellschaft Mit Beschrankter Haftung Process for producing bone cement containing active substances
US20040109894A1 (en) * 2002-12-09 2004-06-10 Adi Shefer PH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
US6759449B2 (en) * 2000-11-28 2004-07-06 Tokuyama Dental Corporation Dental adhesive composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US616033A (en) * 1898-12-13 sturcke
DE2651441C2 (en) * 1976-11-11 1987-01-08 Merck Patent Gmbh, 6100 Darmstadt Antibiotic-containing agent
DE2917037C2 (en) * 1979-04-27 1980-12-11 Josef Dipl.-Chem. Dr. 8000 Muenchen Gaensheimer Parenterally medicinal, partially absorbable multi-component material based on polymeric substances
EP0061108B1 (en) * 1981-03-19 1986-12-30 mundipharma GmbH Bone implant of tricalcium phosphate with mikroporous and macroporous structure, process for its preparation and its use
US5286791A (en) * 1992-05-29 1994-02-15 Himont Incorporated Impact modified graft copolymer compositions containing broad molecular weight distribution polypropylene
KR0139235B1 (en) * 1994-01-29 1998-04-28 조세현 Cement bead composition for orthopaedic surgery and its manufacturing process
US5968999A (en) * 1997-10-28 1999-10-19 Charlotte-Mecklenburg Hospital Authority Bone cement compositions

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3882858A (en) * 1973-04-21 1975-05-13 Merck Patent Gmbh Surgical synthetic-resin material and method of treating osteomyelitis
US4191740A (en) * 1976-11-11 1980-03-04 Merck Patent Gesellschaft Mit Beschrankter Haftung Synthetic resin-base, antibiotic compositions containing amino acids
US4782118A (en) * 1985-06-20 1988-11-01 Ceraver, S.A. Cement for fixing a bone prosthesis
US5958465A (en) * 1996-02-22 1999-09-28 Merck Patent Gesellschaft Apparatus for the production of drug-containing implants in the form of strings of beads
US6160033A (en) * 1996-08-22 2000-12-12 Merck Patent Gesellschaft Mit Beschrankter Haftung Process for producing bone cement containing active substances
US6759449B2 (en) * 2000-11-28 2004-07-06 Tokuyama Dental Corporation Dental adhesive composition
US20040109894A1 (en) * 2002-12-09 2004-06-10 Adi Shefer PH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110112210A1 (en) * 2008-06-30 2011-05-12 Heraeus Medical Gmbh Pmma paste

Also Published As

Publication number Publication date
US8758827B2 (en) 2014-06-24
EP1818039A2 (en) 2007-08-15
US20110062637A1 (en) 2011-03-17
CA2572764A1 (en) 2007-08-10
DE102006006510A1 (en) 2007-08-23
CN101015697A (en) 2007-08-15
EP1818039B1 (en) 2013-07-31
EP1818039A3 (en) 2012-07-04
CN101015697B (en) 2012-05-23
AU2007200072B2 (en) 2009-09-10
JP2007209763A (en) 2007-08-23
JP4686488B2 (en) 2011-05-25
AU2007200072A1 (en) 2007-08-30
BRPI0700258A (en) 2007-11-06
ZA200701174B (en) 2008-07-30

Similar Documents

Publication Publication Date Title
US8758827B2 (en) Local system for the release of active principle and process for its manufacture
AU772291B2 (en) Antibiotic(s)-polymer combination
ES2700677T3 (en) Compositions for bone implant that can initially be deformed plastically
EP1482996B1 (en) Porous biocompatible implant material and method for its fabrication
US5968999A (en) Bone cement compositions
US20040013703A1 (en) Bioabsorbable plugs containing drugs
CN100502954C (en) Bioabsorbable Composite Materials
US20220331492A1 (en) Composition and method for controlled drug release from a tissue
JP2014528734A (en) Bone putty
Niikura et al. Vancomycin-impregnated calcium phosphate cement for methicillin-resistant Staphylococcus aureus femoral osteomyelitis
US7419681B2 (en) Method to enhance drug release from a drug-releasing material
JP2022068212A (en) Scaffold material, methods, and uses
JPH07508433A (en) Granular polymer materials or polymer fibers and their production method
JPH04279520A (en) Pharmaceutical preparation for embedding in bone
Udomkusonsri et al. Elution profiles of cefazolin from PMMA and calcium sulfate beads prepared from commercial cefazolin formulations
US20250302768A1 (en) Nanoparticle doped polyethylene glycol based gels and medical devices for drug delivery
JPH07157439A (en) Formulation for embedding in bone

Legal Events

Date Code Title Description
AS Assignment

Owner name: HERAEUS KULZER GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KUHN, KLAUS-DIETER;VOGT, SEBASTIAN;REEL/FRAME:018912/0658;SIGNING DATES FROM 20070116 TO 20070118

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION